Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

274.02 -6.02 (-2.15%)
Streaming Delayed Price Updated: 10:09 AM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
Madrigal Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease.... 
Via Benzinga
Exposures Product Safety
Why Is Geron (GERN) Stock Up 94% Today?
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today
Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH
The company hopes to be the first to the finish line with a treatment for MASH. 
Via Investor's Business Daily
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers. 
Via The Motley Fool
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
This business could be on the cusp of making medical history. 
Via The Motley Fool
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
The company might have a bright future, but is now the right time to buy shares? 
Via The Motley Fool
Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
2 Rising Biotechs That Could Become the Next Novo Nordisk
Each of these companies has a big market in its sights. 
Via The Motley Fool
2 Stocks That Could Soar This Year: Are They Buys?
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
3 Stocks That Could Be Monster Winners in 2024
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
These 2 Stocks Could Be About to Soar: Are They Buys?
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
These stocks just might have investors seeing double over the next few years. 
Via The Motley Fool
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy: November 2023
Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.